Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Insmed (Nasdaq: INSM) said management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 3:00 p.m. PT / 6:00 p.m. ET. The presentation will be webcast live and available via the company’s investor relations website. Webcasts will be archived for 30 days after the live event.
Positive
- None.
Negative
- None.
News Market Reaction – INSM
In the Jan 2 session, INSM gained 1.77%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 17 | Clinical trial update | Negative | -1.1% | Phase 2b BiRCh CRSsNP study failed endpoints and program discontinued. |
| Dec 09 | Scientific meeting data | Positive | -1.2% | Multiple ERS 2025 abstracts including TPIP Phase 2b and ASPEN subgroup data. |
| Dec 04 | Equity inducement grants | Neutral | -0.8% | Restricted stock units and options granted to 92 new employees. |
| Nov 18 | EU drug approval | Positive | +2.1% | European Commission approval of BRINSUPRI for NCFB patients 12 and older. |
| Nov 13 | CSR initiative | Positive | -1.8% | Fourth annual Global Day of Good with 1,200 employees volunteering worldwide. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has often seen modest price reactions, with generally aligned moves on clearly positive or negative clinical/regulatory updates and some divergences on scientific and CSR news.
Over the past few months, Insmed reported several clinically and strategically important milestones. On Nov 18, EU approval of BRINSUPRI for non‑cystic fibrosis bronchiectasis coincided with a 2.14% gain. A subsequent Dec 17 update disclosed a failed Phase 2b BiRCh study in CRSsNP and program discontinuation, with shares down 1.1%. Other items included inducement equity grants and corporate social responsibility efforts, which saw modest moves. Against this backdrop, a J.P. Morgan 2026 conference appearance fits as a routine investor-relations event rather than a new clinical catalyst.
AI-generated analysis. How Rhea-AI works. Not financial advice.
This event will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Headquartered in
Contact:
Investors:
Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
investor.relations@insmed.com
Media:
Claire Mulhearn
Vice President, Corporate Communications
(862) 842-6819
media@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302648267.html
SOURCE Insmed Incorporated